 This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease SCD e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb-thalassemia subjects. All subjects who have successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator and appropriate consent by subject is given, enroll in the ICA-17043-12 study Study 12. Only patients who participated in ICA-17043-10 are eligible for this open label study 